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A B S T R A C T
Background
An increase in serious adverse events with the use of both regular formoterol and regular salmeterol (long-acting beta2-agonists) in
chronic asthma has been demonstrated in comparison with placebo in previous Cochrane reviews. This increase was significant in
trials that did not randomise participants to an inhaled corticosteroid. However, systematic reviews of trials in which each drug was
randomised with an inhaled corticosteroid did not demonstrate significant increases in serious adverse events. The confidence intervals
were found to be too wide to be sure that the addition of an inhaled corticosteroid renders regular long-acting beta2-agonists completely
safe; there were fewer participants and insufficient serious adverse events in these trials to come to a definitive decision about the safety
of combination treatments.
Objectives
We set out to compare the risks of mortality and non-fatal serious adverse events in trials which have randomised patients with chronic
asthma to regular formoterol versus regular salmeterol, when each are used with an inhaled corticosteroid as part of the randomised
treatment.
Search methods
We identified trials using the Cochrane Airways Group Specialised Register of trials. We checked manufacturers’ websites of clinical
trial registers for unpublished trial data and also checked Food and Drug Administration (FDA) submissions in relation to formoterol
and salmeterol. The date of the most recent search was August 2011.
Selection criteria
We included controlled clinical trials with a parallel design, recruiting patients of any age and severity of asthma, if they randomised
patients to treatment with regular formoterol versus regular salmeterol (each with a randomised inhaled corticosteroid) and were of at
least 12 weeks duration.
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Data collection and analysis
Two review authors independently selected trials for inclusion in the review and extracted outcome data. We sought unpublished data
on mortality and serious adverse events from the sponsors and authors.
Main results
Ten studies on 6769 adults and adolescents met the eligibility criteria of the review. Seven studies (involving 5935 adults and adolescents)
compared formoterol and budesonide to salmeterol and fluticasone. All but one study administered the products as a combined inhaler,
and most used formoterol 12 µg and budesonide 400 µg twice daily versus salmeterol 50 µg and fluticasone 250 µg twice daily. There
were two deaths overall (one on each combination) and neither were thought to be related to asthma.
There was no significant difference between treatment groups (formoterol/budesonide versus salmeterol/fluticasone) for non-fatal
serious adverse events, either all-cause (Peto odds ratio (OR) 1.14; 95% confidence interval (CI) 0.82 to 1.59, I2 = 26%) or asthma-
related (Peto OR 0.69; 95% CI 0.37 to 1.26, I2 = 33%). Over 23 weeks the rates for all-cause serious adverse events were 2.6% on
formoterol and budesonide and 2.3% on salmeterol and fluticasone, and for asthma-related serious adverse events, 0.6% and 0.8%
respectively.
There was one study (228 adults) comparing formoterol and beclomethasone to salmeterol and fluticasone, but there were no deaths
or hospital admissions. One study (404 adults) compared formoterol and mometasone to salmeterol and fluticasone for 52 weeks,
but the small number of events leaves considerable uncertainty about the comparative safety of the two products. Similarly one study
(202 adults) compared formoterol and fluticasone with salmeterol and fluticasone, but there was only one serious adverse event in each
group.
No studies were found in children.
Authors’ conclusions
The seven identified studies in adults did not show any significant difference in safety between formoterol and budesonide in comparison
with salmeterol and fluticasone. Asthma-related serious adverse events were rare, and there were no reported asthma-related deaths. There
was a single, small study comparing formoterol and beclomethasone to salmeterol and fluticasone in adults, a single study comparing
formoterol and mometasone with salmeterol and fluticasone in adults, and a single study comparing formoterol and fluticasone with
salmeterol and fluticasone in adults.
No studies were found in children, so no conclusion can be drawn for this age group.
Overall there is insufficient evidence to decide whether regular formoterol in combination with budesonide, beclometasone, fluticasone
or mometasone have equivalent or different safety profiles from salmeterol in combination with fluticasone.
P L A I N L A N G U A G E S U M M A R Y
Do people with asthma have fewer serious adverse events when taking formoterol and inhaled corticosteroids or salmeterol and
inhaled corticosteroids?
Asthma is a condition that affects the airways - the small tubes that carry air in and out of the lungs. When a person with asthma comes
into contact with an asthma trigger, their airways become irritated and the muscles around the walls of the airways tighten so that the
airways become narrower (bronchoconstriction) and the lining of the airways becomes inflamed and starts to swell. Sometimes, sticky
mucus or phlegm builds up, which can further narrow the airways. These reactions cause the airways to become narrower and irritated
- making it difficult to breathe and leading to coughing, wheezing, shortness of breath and tightness in the chest. People with asthma
are generally advised to take inhaled steroids to combat the underlying inflammation, but if asthma is still not controlled, current
clinical guidelines for people with asthma recommend the introduction of an additional medication to help. A common strategy in
these situations is to use a long-acting beta-agonists: formoterol or salmeterol. A long-acting beta-agonist is an inhaled drug which
opens the airways (bronchodilator) making it easier to breath.
We know from previous Cochrane reviews that there is a small increase in serious adverse events (such as very severe asthma attacks as
well as other life-threatening events) when either of regular formoterol and regular salmeterol are compared with placebo treatment in
patients who are not also taking inhaled steroids. This review sought information from trials that compared the two treatments (i.e.
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when people taking salmeterol with an inhaled corticosteroid were compared directly with people taking formoterol and an inhaled
corticosteroid) to see if we could determine which drug was the safest.
We found 10 trials on 6769 adults and adolescents, but we did not find any trials on children. We found no significant difference
between the treatments, but serious adverse events were too rare to be confident that the risks are the same for both treatments. There
are no trials in children; we therefore could not draw any conclusions for children and so more trials are needed.
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B A C K G R O U N D
Whenpatients with asthma are not controlled by low-dose inhaled
corticosteroids alone, many asthma guidelines recommend addi-
tional long-acting beta2-agonists. Several Cochrane reviews have
addressed the efficacy of long-acting beta2-agonists given with in-
haled corticosteroids (Ni Chroinin 2009; Ni Chroinin 2010), in
comparison with placebo (Walters 2007), short-acting beta2-ago-
nists (Walters 2002), leukotriene-receptor antagonists (Ducharme
2011) and increased doses of inhaled corticosteroids (Ducharme
2010). The beneficial effects of long-acting beta2-agonists on lung
function, symptoms, quality of life and exacerbations requiring
oral steroids have been demonstrated, and a rationale has been
put forward for their use in combination with an inhaled corti-
costeroid (Barnes 2002).
Concern remains that regular treatment with long-acting beta2-
agonists might lead to an increase in asthma-related deaths (as seen
in SMART 2006). Regular treatment with beta2-agonists can lead
to tolerance to their bronchodilator effects with both long-act-
ing and short-acting compounds (Lipworth 1997). A number of
molecular mechanisms have been proposed to explain the possible
detrimental effect of long-term beta2-agonist use in asthma, in-
cluding receptor down-regulation and desensitisation (Giembycz
2006).
A recent meta-analysis of the effect of long-acting beta2-ago-
nists on severe asthma exacerbations and asthma-related deaths
(Salpeter 2006) concluded that “long-acting beta-agonists have
been shown to increase severe and life-threatening asthma exac-
erbations, as well as asthma-related deaths”. Salpeter 2006 con-
sidered trials that compared any long-acting beta2-agonists with
placebo, and the review was not able to include 28 trials in the
primary analysis (including nearly 6000 patients) because infor-
mation was not provided for asthma-related deaths.
Currently there are two long-acting beta2-agonists available, sal-
meterol and formoterol (also known as eformoterol). These two
drugs are known to have differences in speed of onset and receptor
activity, and are used in different ways (for example, salmeterol has
a slower onset of action than salbutamol, Beach 1992). For this
reason we have considered salmeterol and formoterol separately in
our previous work.
Two of our published reviews have assessed the risk of fatal and
non-fatal serious adverse events with regular salmeterol (Cates
2008) and formoterol (Cates 2008a) in comparison to placebo
or short-acting beta2-agonists. In comparison to placebo, adults
on regular salmeterol and children on regular formoterol demon-
strated a significant increase in all-cause non-fatal serious adverse
events. Two further reviews, in which each drug was randomised
with an inhaled corticosteroid in comparison to the same dose of
the inhaled corticosteroid have also been completed (Cates 2009;
Cates 2009a). These did not demonstrate significant increases in
serious adverse events, but the confidence intervals are too wide
to be sure that the addition of an inhaled corticosteroid renders
regular long-acting beta2-agonists completely safe. Moreover, in-
direct comparisons on the relative safety of formoterol and sal-
meterol from the results of these existing reviews are subject to
confounding due to differences in the participants, interventions,
comparisons and outcomes in the trials of each review.
A review comparing the safety of regular formoterol and salmeterol
without a randomised inhaled corticosteroid has also been carried
out from trials that have made head-to-head comparisons of the
two products (Cates 2009b). The trials that were included inCates
2009b turned out to have used background inhaled corticosteroids
in all participants. However, no previous review has compared
regular formoterol to regular salmeterol from trials in which an
inhaled corticosteroid was a mandatory part of the randomised
treatment. We have considered this to be a separate question, as
adherence with an inhaled corticosteroid may be better when it
is part of the randomised treatment schedule (particularly if a
combined inhaler is used).
This review, therefore, sets out to compare the safety of regular
formoterol and regular salmeterol when each is used in combina-
tion with a randomised inhaled corticosteroid.
O B J E C T I V E S
To assess the risk of mortality and non-fatal serious adverse events
in trials which have randomised patients with chronic asthma to
regular formoterol and an inhaled corticosteroid versus regular
salmeterol and an inhaled corticosteroid.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included controlled, parallel-design clinical trials, with orwith-
out blinding, in which patients with chronic asthma were ran-
domly assigned to regular treatment with formoterol and an in-
haled corticosteroid versus salmeterol and an inhaled corticos-
teroid. We excluded studies on acute asthma and exercise-induced
bronchospasm.
Types of participants
We included patients with a clinical diagnosis of asthma of any
age group, unrestricted by disease severity, previous or current
treatment.
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Types of interventions
We included trials randomising patients to formoterol versus sal-
meterol given regularly in combination with an inhaled corticos-
teroid at any dose and delivered at fixed dose by any single or
separate devices (chlorofluorocarbon metered dose inhaler (CFC-
MDI); hydrofluoroalkane metered dose inhaler (HFA-MDI); dry
powder inhaler (DPI)) for a period of at least 12 weeks. We ex-
cluded studies that used adjustable maintenance dosing and single
inhaler therapy (for maintenance and relief of symptoms).
Types of outcome measures
Primary outcomes
1. All-cause mortality
2. All-cause non-fatal serious adverse events (see definition
below)
Secondary outcomes
1. Asthma-related mortality
2. Asthma-related non-fatal serious adverse events
3. Cardiovascular-related mortality
We did not subdivide outcomes according to whether the trial
investigators considered them to be related to trial medication. We
accepted trial investigators’ judgement of whether serious adverse
events were asthma-related or not.
An assessment of efficacy outcomes (such as exacerbations, symp-
toms and lung function) of these drug combinations when co-
delivered via the same inhaler has been undertaken and published
elsewhere (Lasserson 2008).
Definition of serious adverse events
The Expert Working Group (Efficacy) of the International Con-
ference on Harmonisation of Technical Requirements for Regis-
tration of Pharmaceuticals for Human Use (ICH) define serious
adverse events as follows (ICHE2a 1995):
“A serious adverse event (experience) or reaction is any untoward
medical occurrence that at any dose:
• results in death,
• is life-threatening,
• requires inpatient hospitalization or prolongation of
existing hospitalization,
• results in persistent or significant disability/incapacity, or
• is a congenital anomaly/birth defect.
NOTE: The term ”life-threatening“ in the definition of ”serious“
refers to an event in which the patient was at risk of death at the
time of the event; it does not refer to an event which hypothetically
might have caused death if it were more severe.”
Search methods for identification of studies
Electronic searches
We identified trials using theCochrane Airways Group Specialised
Register of trials, which is derived from systematic searches of
bibliographic databases including the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL), MEDLINE, EMBASE,
CINAHL, AMED and PsycINFO, and handsearching of respira-
tory journals and meeting abstracts (please see Appendix 1). We
searched all records in the Specialised Register coded as ’asthma’
using the following terms:
(((salmeterol or serevent) AND (formoterol or eformoterol or oxis
or foradil) AND (steroid* or corticosteroid* or ICS or fluticas-
one or FP or Flixotide or budesonide or BUD or Pulmicort or
beclomethasone or becotide or becloforte or becodisk or QVAR
or ciclesonide or triamcinolone or flunisolide or mometasone))
OR (Symbicort or Viani or Seretide or Advair or Inuvair)) AND
(serious or safety or surveillance or mortality or death or intubat*
or adverse or toxicity or complications or tolerability)
In addition we carried out a second search just using the terms:
(salmeterol or serevent) AND (formoterol or eformoterol or oxis
or foradil).
The date of the most recent search was August 2011.
Searching other resources
We checked reference lists of all primary studies and review arti-
cles for additional references. We checked websites of clinical trial
registers for unpublished trial data and we also checked FDA sub-
missions in relation to salmeterol and formoterol.
Data collection and analysis
Selection of studies
One review author (CJC) independently assessed studies identi-
fied in the literature searches by examining titles, abstracts and
keyword fields. We obtained studies that potentially fulfilled the
inclusion criteria in full text. Two review authors (CJC and TL)
independently assessed full-text articles for inclusion. No disagree-
ments occurred.
Data extraction and management
One review author (CJC) extracted data using a prepared checklist
and entered data into RevMan 5. The second review author (TL)
independently checked the data extraction and entry.We extracted
data on characteristics of included studies (methods, participants,
interventions, outcomes) and results of the included studies. We
contacted authors and sponsors of included studies for unpub-
lished adverse event data and searched manufacturers’ websites for
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further details of adverse events. We also searched FDA submis-
sions. We recorded all-cause serious adverse events (fatal and non-
fatal) and in view of the difficulty in deciding whether events are
asthma-related, noted details of the cause of death and serious ad-
verse events. We requested further information when causation
was not clear (particularly in relation to hospital admissions and
serious adverse events).
Assessment of risk of bias in included studies
One review author (CJC) assessed the included studies for bias
protection (including sequence generation for randomisation, al-
location concealment, blinding of participants and assessors, loss
to follow-up, completeness of outcome assessment and other pos-
sible bias prevention). We judged risk of bias as either high, low or
unclear according to recommendations in theCochrane Handbook
of Systematic Reviews of Interventions (Higgins 2008).
Unit of analysis issues
We confined our analysis to patients with one or more serious
adverse events, rather than the number of events that occurred (as
the latter are not independent when one patient suffers multiple
events).
Assessment of heterogeneity
We assessed heterogeneity using the I2 statistic to indicate how
much of the total heterogeneity found was between, rather than
within studies.
Assessment of reporting biases
We planned to inspect funnel plots to assess publication bias.
Data synthesis
The outcomes of this review were dichotomous and we recorded
the number of participants with one or more of each outcome
event, by allocated treated group.We calculated pooled odds ratios
(OR) and risk differences (RD).The Peto odds ratio has advantages
when events are rare, as no adjustment for zero cells is required.
This property was found in previous reviews to be more important
than potential problems with unbalanced treatment arms, and
we therefore calculated the results for serious adverse events in
RevMan 5 using the Peto method with Mantel-Haenszel methods
for sensitivity analysis.
Subgroup analysis and investigation of heterogeneity
We planned subgroup analyses on the basis of age (adults versus
children) and dose of inhaled corticosteroids (equivalence between
arms or not). We planned to compare subgroups using tests for
interaction (Altman 2003).
Sensitivity analysis
We carried out sensitivity analysis to assess the impact of the
method used to combine the study events (risk difference, Peto
odds ratio and Mantel-Haenszel odds ratio). We conducted a sen-
sitivity analysis on the degree of bias protection in the study de-
signs.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
We carried out the original search for relevant studies in January
2009 and identified 106 potentially relevant abstracts. We ob-
tained 12 abstracts as full articles and included seven abstracts re-
lating to six studies (Aalbers 2004; Busse 2008; Dahl 2006; Kuna
2007; Papi 2007; Ringdal 2002). We excluded three review arti-
cles (Bleecker 2008;Dhillon2006; Lyseng-Williamson 2003)with
reasons provided in Characteristics of excluded studies. We also
carried out an extended search in which the adverse event terms
were excluded, and this identified a further 184 abstracts; from
these we obtained 17 further full-text articles. We included two
further studies from the GSK trials register (SAM 40010; SAM
40048); excluded one study (Lee 2003) and the other articles were
all additional references to studies that had already been included.
A total of eight studies reported in 35 separate references met the
eligibility criteria of the review.
A subsequent search in July 2009 did not identify any further
studies for inclusion, but there were two further potentially rele-
vant studies that we subsequently excluded (Hampel 2008; Jung
2008), see Characteristics of excluded studies for further details.
In August 2011 a further search identified three new citations
for studies already included (Aalbers 2004; Busse 2008; Kuna
2007), three citations for a new study comparing formoterol and
fluticasone with salmeterol and fluticasone (Bodzenta-Lukaszyk
2011) and six citations for a new study on 404 adults compar-
ing formoterol and mometasone with salmeterol and fluticasone
(Maspero 2010).
Included studies
Dose and delivery of medication
Overall in seven studies 5935 adults were randomised to for-
moterol and budesonide versus salmeterol and fluticasone; 228
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adults were randomised to formoterol and extra-fine beclometha-
sone versus salmeterol and fluticasone in Papi 2007, 202 adults
were randomised to formoterol and fluticasone or salmeterol and
fluticasone in Bodzenta-Lukaszyk 2011 and 404 adults were ran-
domised to formoterol and mometasone or salmeterol and fluti-
casone in Maspero 2010.
Details of the delivery devices and doses of the medication in each
trial are given in Table 1. All the studies used combination inhalers
except for Ringdal 2002, in which formoterol and budesonide
were administered in separate inhalers. We judged the dose of
inhaled corticosteroid in each arm to be equivalent except in
Ringdal 2002 (higher-dose budesonide) and SAM40048 (higher-
dose fluticasone), see Table 1. Whilst most studies compared 12
µg formoterol twice daily with 50 µg salmeterol twice daily, SAM
40010 and SAM 40048 compared 6 µg formoterol with 50 µg
salmeterol twice daily.
Run-in period
In all studies except Busse 2008 and Bodzenta-Lukaszyk 2011, the
participants continued their previous treatment with inhaled cor-
ticosteroids alone during the run-in period (those previously on
long-acting beta2-agonist (LABA) were either excluded or discon-
tinued LABA treatment), and were enrolled in the study if they
were symptomatic at the end of run-in. Busse 2008 allowed in-
haled corticosteroids (ICS) and LABA/ICS to be continued during
run-in, but participants still had to be symptomatic to be enrolled
into the study. Bodzenta-Lukaszyk 2011 did not specify treatment
details for the screening phase of 4 to 10 days to evaluate eligibility,
and Maspero 2010 kept participants on their previous medication
during screening.
Age of participants
No studies were found in children. The lower age limit in the
studies varied from 12 years old (Aalbers 2004; Busse 2008; Kuna
2007;Maspero 2010; SAM40010; SAM40048) to 16 or 18 years
(Bodzenta-Lukaszyk 2011; Dahl 2006; Papi 2007; Ringdal 2002).
Sponsorship and location
All the included studies were sponsored by one of themanufactur-
ers of combined inhalers, and the duration and location of studies
are shown in Table 2.
Risk of bias in included studies
Figure 1 shows an overview of the potential risks of bias in each
study
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
We judged sequence generation and allocation concealment to be
adequate in six studies (Aalbers 2004; Bodzenta-Lukaszyk 2011;
Dahl 2006; Kuna 2007; Papi 2007; Ringdal 2002). The meth-
ods used were not clearly reported in four studies (Busse 2008;
Maspero 2010; SAM 40010; SAM 40048).
Blinding
Four studies had well-reported methods of blinding (Dahl 2006;
Kuna 2007; Ringdal 2002; SAM 40010) and four studies were
open label (Aalbers 2004; Bodzenta-Lukaszyk 2011; Busse 2008;
Maspero 2010) but one of these (Maspero 2010) reported that
there was evaluator blinding. SAM 40048 was unclear and Papi
2007 did not use a double-dummy design but encased the inhalers
in a non-removable covering.
Incomplete outcome data
All studies, with the exception of Aalbers 2004, reported that at
least 80%of participants completed the study and inmost cases the
completion rate was 90% or above (see Characteristics of included
studies for details of individual studies).
Selective reporting
Full data on serious adverse events have been obtained from all
studies.
Other potential sources of bias
All the studies have been sponsored by manufacturers of com-
bined long-acting beta2-agonist and inhaled corticosteroid in-
halers. None of the studies had independent assessment of the
cause of serious adverse events, whichmay present risk of bias when
considering asthma-related events (rather than all-cause events).
Effects of interventions
See: Summary of findings for the main comparison Regular
formoterol and budesonide compared to regular salmeterol and
fluticasone for chronic asthma
Formoterol/budesonide versus salmeterol/fluticasone
Mortality
Two deaths were reported in 5935 adult and adolescent partici-
pants and neither was asthma-related. In SAM 40010 there was
one death in formoterol/budesonide group due to gastrointestinal
obstruction, cardiac failure and septic shock. In Kuna 2007 there
was one death in the salmeterol/fluticasone group due to cardiac
failure. The pooled results do not show a significant difference
in all-cause mortality using Peto odds ratio (Peto OR 1.03; 95%
confidence interval (CI) 0.06 to 16.44, I2 = 50%) (see Figure 2),
or risk difference (RD 0.000009; 95% CI -0.002 to 0.002, I2 =
0%).
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Figure 2. Forest plot of comparison: 1 Fixed-dose formoterol/ICS versus salmeterol/fluticasone, outcome:
1.1 All-cause mortality.
There is insufficient information to consider asthma-related or
cardiovascular-related mortality (which were secondary outcomes
in our protocol).
All-cause non-fatal serious adverse events
There were 77 out of 2966 adults and adolescents on formoterol
and budesonide who suffered one or more serious adverse events,
compared to 68 out of 2969 patients on salmeterol and fluticasone.
This is not a significant difference when combined as an odds ratio
(Peto OR 1.14; 95% CI 0.82 to 1.59, I2 = 26%) (see Figure 3),
or as a risk difference (RD 0.003; 95% CI -0.005 to 0.011, I2 =
21%).
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Figure 3. Forest plot of comparison: 1 Fixed-dose formoterol/ICS versus salmeterol/fluticasone, outcome:
1.2 All-cause non-fatal serious adverse events.
Busse 2008 reported nine participants who suffered a serious ad-
verse event in each arm of the trial (table S4 of the paper), but
one additional participant on formoterol/budesonide was admit-
ted to hospital on treatment for an episode that was judged to have
started during run-in. Another participant had a serious adverse
event after the last dose of randomised treatment, but correspon-
dence with the sponsors indicated that this participant had already
suffered a serious adverse event on treatment, and so was already
included. We therefore decided to enter 10 participants for the
formoterol/budesonide arm of this trial. We carried out sensitivity
analysis to assess the impact of excluding the additional patient in
the formoterol/budesonide arm and the results showed very little
difference in the odds ratio (Peto OR 1.13; 95% CI 0.81 to 1.57,
I2 = 27%) as shown in Figure 4.
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Figure 4. Forest plot of comparison: 1 Fixed-dose formoterol/ICS versus salmeterol/fluticasone, outcome:
1.2 All-cause non-fatal serious adverse events (without the additional participant on formoterol/budesonide in
Busse 2008).
Asthma-related non-fatal serious adverse events
For two studies we were not able to find published reports of the
number of patients who had suffered one or more asthma-related
serious adverse events in the paper, but we were able to obtain this
information from the sponsor (Busse 2008; Kuna 2007). Overall
there were 17 adults and adolescents out of 2966 on formoterol
and budesonide with asthma-related serious adverse events, and 25
out of 2969 on salmeterol and fluticasone. This is not a significant
difference when combined as an odds ratio (Peto OR 0.69; 95%
CI 0.37 to 1.26, I2 = 33%) (see Figure 5), or as a risk difference
(RD -0.003; 95% CI -0.007 to 0.002, I2 = 0%).
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Figure 5. Forest plot of comparison: 1 Fixed-dose formoterol/ICS versus salmeterol/fluticasone, outcome:
1.3 Asthma related non-fatal serious adverse events.
The number of patients who were admitted to hospital in Dahl
2006 on salmeterol and fluticasone was recorded as four, which
is lower than the six patients recorded as having asthma-related
serious adverse events in this review. The reason for this difference
has been clarified following correspondence with GlaxoSmithK-
line and relates to one patient who suffered acute bronchospasm
but was not admitted to hospital, and a second patient who was
admitted to hospital but had an exacerbation that had started in
the run-in period.
Formoterol/beclomethasone versus
salmeterol/fluticasone
No serious adverse events (fatal or non-fatal) were reported in the
single trial in the 228 adult participants from Papi 2007.
Formoterol/mometasone versus
salmeterol/fluticasone
Mortality
Two deaths occurred in the single study of this comparison
(Maspero 2010) and both were taking mometasone (see Figure 2).
One was due to electrocution and one due to gastric cancer.
All-cause non-fatal serious adverse events
There were similar proportions of participants with non-fatal seri-
ous adverse events of any cause on both formoterol/mometasone
and salmeterol/fluticasone, but the confidence intervals are too
wide to conclude that the safety of the two products is equivalent
(Peto OR 1.07; 95% CI 0.40 to 2.84) (see Figure 3).
Asthma-related serious adverse events were not reported from this
study.
Formoterol/fluticasone versus salmeterol/fluticasone
One serious adverse event was reported in each arm of a single
study comparing formoterol/fluticasone versus salmeterol/flutica-
sone in 202 adult participants fromBodzenta-Lukaszyk 2011. The
trial report states: “Serious AEs (SAEs) were also reported for one
patient in each treatment group. The SAEs experienced by the
patient in the fluticasone/formoterol group (haemorrhagic stroke
and cardiac arrest, approximately 2 months after randomization)
led to withdrawal from the study, and had a fatal outcome. The
SAE reported in the fluticasone/salmeterol group was pneumo-
coccal pneumonia.”
These numbers are too small to make any meaningful comparison
of the relative safety of the two treatments.
Sensitivity analysis
We carried out sensitivity analysis, excluding the two unblinded
studies (Aalbers 2004; Busse 2008). Restricting the analysis to
the blinded studies had no impact on mortality (as there were
no deaths in either of the open studies). All-cause serious adverse
events in the blinded studies showed no significant difference (Peto
OR 1.05; 95% CI 0.72 to 1.53, I2 = 34%), and similarly asthma-
related events were also not significant (Peto OR 0.74; 95% CI
0.39 to 1.39, I2 = 23%).
Subgroup analysis
Subgroup analysis was not possible on the basis of age, as there
were no studies in children. We did not attempt subgroup analysis
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on the basis of dose equivalence of inhaled corticosteroids or long-
acting beta2-agonists as the data were too sparse.
Publication bias
It was possible to obtain data on serious adverse events from all
the studies. A funnel plot was not appropriate as there were fewer
than 10 studies included.
D I S C U S S I O N
Summary of main results
Ten studies involving adults and adolescents are included in this
review. Seven of these (N =5935) compared formoterol and budes-
onide to salmeterol and fluticasone, mostly using combined in-
halers. One trial (N = 228) compared formoterol and beclometha-
sone to salmeterol and fluticasone, but this study included no hos-
pital admissions or deaths, so it has not been possible to assess sa-
fety for this comparison. One trial (N = 404) compared formoterol
and mometasone to salmeterol and fluticasone and one trial (N
= 202) compared formoterol and fluticasone with salmeterol and
fluticasone. There were no identified studies in children. The stud-
ies recruited participants who were previously treated with mod-
erate to high doses of inhaled steroids.
No significant differences have been found between combination
treatment on formoterol with inhaled corticosteroids and salme-
terol with fluticasone for all-cause mortality in adults and ado-
lescents, nor for non-fatal adverse events of any cause or events
related to asthma.
Overall completeness and applicability of
evidence
Whilst the included studies were sufficiently powered for equiva-
lence in terms of the primary efficacy outcomes (e.g. Papi 2007),
they remain underpowered to detect possible important differ-
ences in serious adverse events (Cates 2008). Therefore, whilst no
significant differences have been found between the combination
inhalers, the confidence intervals are too wide to determine equiv-
alence of safety.
Quality of the evidence
The studies were generally well protected against bias (see Figure
1). Allocation concealment and sequence generation did not
present undue risk of bias in the included studies, and results on
serious adverse events have been obtained from all the studies.
Aalbers 2004, Bodzenta-Lukaszyk 2011, Busse 2008 andMaspero
2010 were open studies, and Aalbers 2004 had a withdrawal rate of
over 20%.We carried out sensitivity analysis using only the blinded
studies and there was still no significant difference between the
treatments. Consideration of asthma-related adverse events might
have been subject to bias as none of the trials used independent
outcome assessment for causation of adverse events.
Potential biases in the review process
Since the included studies were designed to assess efficacy, it seems
unlikely that publication bias would take the formof whole studies
remaining unreported. It is, however, apparent that the reporting
of serious adverse events in medical journals is suboptimal (Cates
2008). In this review it has been possible to obtain serious adverse
event data from all studies, following correspondence with the trial
sponsors. We therefore feel that there is a low risk of publication
bias for this review.
Agreements and disagreements with other
studies or reviews
Previous reviews have identified an increased risk of serious ad-
verse events with regular salmeterol (Cates 2008) and regular for-
moterol (Cates 2008a) when compared to placebo. In contrast, in
studies that used randomised inhaled corticosteroids, no signifi-
cant increase in serious adverse events has been shown with regu-
lar salmeterol (Cates 2009a) or regular formoterol (Cates 2009).
However, the confidence intervals in the latter reviews were too
wide to conclude that the addition of an inhaled corticosteroid
renders regular formoterol or salmeterol completely safe. It is in
keeping with these latter reviews that we have found no signifi-
cant difference between regular salmeterol and regular formoterol
when used with a randomised inhaled corticosteroid in this re-
view. The results of this review are also similar to Cates 2009b,
which found no significant difference between formoterol and sal-
meterol in which all participants used background (rather than
randomised) inhaled corticosteroids.
The negative findings may be partly an issue of statistical power,
as very large numbers of patients would need to be randomised to
identify small differences between salmeterol and formoterol. We
do not have enough information to rule out clinically important
differences between salmeterol and formoterol from the available
studies, as the events are too sparse to generate tight confidence
intervals.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
No significant differences have been found between formoterol
and budesonide and salmeterol and fluticasone treatment in stud-
ies on 5935 adults, nor between formoterol and beclomethasone
and salmeterol and fluticasone in 228 adults, nor between for-
moterol and mometasone and salmeterol and fluticasone in 404
adults, or between formoterol and fluticasone and salmeterol and
fluticasone in 202 adults. Small numbers of patients experienced
serious adverse events and the confidence intervals around the
combined results are wide, so we have not been able to demon-
strate whether the products are equivalent in terms of safety.
Implications for research
No safety studies comparing formoterol and salmeterol have been
carried out in children. A large double-blind, double-dummy
study in children comparing the combined inhalers with the same
inhaled corticosteroid alone (in a four-arm, parallel-group design)
is required to assess the relative safety of formoterol and salme-
terol in this age group. Further research is also required to clarify
the risk-benefit ratio of combination products in adults as well as
children
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aalbers 2004
Methods A randomised, double-blind/open-extension, double-dummy, multicentre, parallel-
group study over 4 weeks from October 2001 to December 2002 at outpatient clinics
in 93 centres in 6 countries (Denmark (9), Finland(10), Germany (11), the Netherlands
(12), Norway (41) and Sweden (10)). Open run-in 10 to 14 days)
The open extension period was for 6 months in which 2 arms of the study continued
on fixed-dose BDF and FPS
Participants 658 adolescents and adults (12 to 85) years with perennial asthma
Baseline characteristics: mean age 46 years. FEV1 84%predicted. Concomitant inhaled
corticosteroids used by 100% of participants, mean dose 735 µg/day. Run-in on previous
dose of ICS alone (LABA discontinued in the 28% of participants taking it previously)
Inclusion criteria: aged 12 years or over with a diagnosis of perennial asthma and using
between 500 to 1200 µg daily of inhaled GCS. FEV1 % predicted of 50% or greater.
Must have had a total asthma symptom score of at least 1 on at least 4 of the last 7 days of
the run-in period and a mean morning peak expiratory flow (PEF) during the last 7 days
of the run-in period of between 50% and 85% of post bronchodilatory PEF measured
at Visit 1 or 2. Run-in on previous ICS alone
Exclusion criteria: respiratory infection affecting asthma within 1 month of study entry,
smoking history of more than 10 pack-years, use of systemic corticosteroids within 1
month of study entry and any significant disorder which, in the opinion of the investi-
gator, may have put the patient at risk or influenced the study
Interventions 1. Salmeterol/fluticasone 50/250 µg bd x 1 DPI
2. Budesonide/formoterol 160/4.5 µg bd x 2 DPI
3. The third arm was on adjustable maintenance dose and not used in this review
Outcomes The primary efficacy endpoint was the odds of having a well-controlled asthma week
during the randomised treatment period. SAE reported in the paper for each group. No
deaths occurred in the study (web report)
Notes Sponsored by AstraZeneca
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation schedule was generated
using a computer program by a statistician
independent of the study team
Allocation concealment (selection bias) Low risk Patients were consecutively allocated to the
lowest available patient number and were
randomised strictly sequentially in blocks
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Aalbers 2004 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding in the 6-month open exten-
sion period
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 575/658 (76%) completed the study, with
similar loss in all groups
Selective reporting (reporting bias) Low risk SAE reported in paper for each group
Independent Outcome Assessment
Asthma-related serious adverse events
High risk No independent outcome assessment
Bodzenta-Lukaszyk 2011
Methods Study design: this was a 12-week, open-label, randomised, active-controlled, parallel-
group, phase 3 study, conducted at 25 centres across 5 European countries (Germany,
Hungary, Poland, Romania and the UK; clinicaltrials.gov identifier: NCT00476073)
Participants Population: 202 adults (18+) years with patients with mild-to-moderate-to-severe per-
sistent asthma
Baseline characteristics:mean age 47 years. FEV1 67%predicted.Concomitant inhaled
corticosteroids used by 93% of participants
Inclusion criteria: patients were required to demonstrate a FEV1 of ≥ 40% and ≤
85% of predicted normal values (17) during the screening phase following appropriate
withholding of asthma medications (if applicable). Patients were also required to show
reversibility of ≥ 15% in FEV1 after salbutamol inhalation (2 actuations, 100 µg per
actuation) in order to be eligible for randomisation.Only patientswho could demonstrate
correct inhaler technique were entered into the study
Exclusion criteria: life-threatening asthma within the past year; hospitalisation or emer-
gency department visit for asthma in the 4 weeks prior to screening; systemic corticos-
teroid use in the month prior to screening; omalizumab use in the past 6 months; use
of a leukotriene receptor antagonist in the week before screening; a smoking history
that was either recent (in the 12 months prior to screening) or equivalent to ≥ 10 pack
years (e.g. at least 20 cigarettes/day for 10 years); significant non-reversible active pul-
monary disease; and clinically significant respiratory tract infection in the 4 weeks prior
to screening. Also prohibited was recent use (in the past week) of b-blocking agents, tri-
cyclic antidepressants, monoamine oxidase inhibitors, astemizole, quinidine-type anti-
arrhythmics or potent CYP3A4 inhibitors. Current use of medications that would have
an effect on bronchospasm and/or lung function was also a criterion for exclusion
Interventions Patients randomised to receive fluticasone/formoterol were to take 2 actuations of 50/5
µg or 125/5 µg every 12 hours (i.e. 100/10 µg or 250/10 µg twice daily).
Patients randomised to receive fluticasone/salmeterol were to take 2 actuations of 50/25
µg or 125/25 µg every 12 hours (i.e. 100/50 µg or 250/50 µg twice daily).
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Bodzenta-Lukaszyk 2011 (Continued)
Both study treatments were administered via a hydrofluoroalkane pressurised metered-
dose inhaler with an AeroChamber® Plus spacer device
Patients receiving the low dose of study medication were permitted to switch to the high
dose during the treatment period if their asthma was not controlled, at the investigator’s
discretion
Outcomes Primary outcome: FEV1
SAE results reported in the paper:
“SeriousAEs (SAEs)were also reported for one patient in each treatment group.The SAEs
experienced by the patient in the fluticasone/formoterol group (haemorrhagic stroke and
cardiac arrest, approximately 2 months after randomization) led to withdrawal from the
study, and had a fatal outcome. The SAE reported in the fluticasone/ salmeterol group
was pneumococcal pneumonia.”
Notes Sponsored by Mundipharma Research Limited
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random permuted block design
Allocation concealment (selection bias) Low risk Eligible patients were assigned a unique
randomisation number selected sequen-
tially from a randomisation list via an in-
teractive voice randomisation system
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7% and 6% withdrawn from each arm
Selective reporting (reporting bias) Low risk SAE events reported in paper for each
group
Independent Outcome Assessment
Asthma-related serious adverse events
High risk No independent outcome assessment re-
ported
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Busse 2008
Methods Study design: a randomised, open-label, multicentre, parallel-group, Phase III study
over 7 months at 145 centres in the United States. Run-in 10 to 14 days.
The study comprised 3 phases: run-in (10 to 14 days), treatment period 1 (1 month, fixed-
dose regimens), treatment period 2 (6 months, adjustable-dose or fixed-dose regimens).
Participants Population: 1225 adolescents and adults (12 to 87) years with moderate-to-severe per-
sistent asthma
Baseline characteristics: mean age 39 years. FEV1 78.7% predicted. Concomitant in-
haled corticosteroids used by 100% of participants. Mean dose 550 µg/day. Run-in on
previous asthma therapy (ICS or LABA/ICS)
Inclusion criteria: patients aged 12 years and older with a documented diagnosis of
asthma, as defined by the American Thoracic Society for 6 months or more before
screening andwhowere in stable condition. To have beenmaintained on a dailymedium-
dose ICS or ICS/LABA combination for 12 weeks or longer before screening. FEV1 %
predicted of 50% or greater 6 or more hours after short-acting beta2 -adrenergic agonist
use and 24 or more hours after LABA use, had received 8 or more inhalations of albuterol
during the last 10 days of the run-in period and demonstrated a mean morning peak
expiratory flow (PEF) of between 50% and 85% of the PEF value obtained 15 minutes
after albuterol pMDI (2 to 4 inhalations (90 µg per inhalation)) during the last 7 days
of the run-in period.
Exclusion criteria: systemic corticosteroid use within 30 days before screening, a 20 or
more pack-year smoking history at screening, or a significant disease, respiratory tract
infection, or illness that might interfere with the patient’s lung function or participation
in the study
Interventions 1. Fluticasone/salmeterol 250/50 µg BD DPI
2. Budesonide/formoterol 320/9 µg BD pMDI
The AMD treatment arm was not included in this review
Outcomes The primary efficacy variable was asthma control, as assessed by asthma exacerbations
SAE results reported on the sponsor’s website. Uncertainty over the 2 participants men-
tioned in the footnotes to table S4 in the report from the trial register was resolved after
correspondence with the sponsors. The participant who suffered a SAE after finishing
treatment had already been counted in the formoterol/budesonide arm due to another
SAE whilst on treatment, but the patient who was admitted to hospital for an episode
that was judged to have started during run-in had not been included in the 9 participants
on formoterol/budesonide. After discussion we therefore used 10 for this arm in our
primary analysis
Notes Sponsored by AstraZeneca
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation schedule was com-
puter-generated
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Busse 2008 (Continued)
Allocation concealment (selection bias) Low risk The site called in to an IVRS which as-
signed subjects the next lowest available
randomisation number
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding in 6-month study extension
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1052/1225 (86%) completed the study
Selective reporting (reporting bias) Low risk SAE data found on website
Independent Outcome Assessment
Asthma-related serious adverse events
High risk No independent outcome assessment
Dahl 2006
Methods Study design: a randomised, double-blind, double-dummy, multicentre, parallel-group
study over 24weeks fromNovember 2001 to January 2003 at 178 centres in 18 European
countries. Run-in 2 weeks
Participants Population: 1397 adults (18 to 91) years with patients with moderate-to-severe asthma
Baseline characteristics: mean age 46 years. FEV1 78.6% predicted. Concomitant
inhaled corticosteroids used by 100% of participants. Run-in on previous dose of ICS
alone; LABA (if previously used) was withdrawn during the run-in period
Inclusion criteria: aged 18 years or over, with a documented clinical history of asthma
of at least 6 months and receiving 1000 to 2000 µg/day of beclomethasone dipropionate
or equivalent. Combination therapy, if used, was discontinued and replaced with ICS
alone, at least 4 weeks prior to study start (screening visit). Bronchodilator reversibility
by an increase of at least 12% in FEV1 15 min after inhaling salbutamol 200 to 400 µg.
For the randomised treatment period (baseline), bronchodilator reversibility by an in-
crease of at least 12% in FEV1 (and > 200 mL), 15 min after inhaling salbutamol 200
to 400 µg, and an asthma symptom score (day and night combined) of at least 2 (2 or
more episodes of symptoms during the day/night) on at least 4 of the last 7 evaluable
days of the run-in period.
Exclusion criteria: suffered an upper or lower respiratory tract infection or an acute
asthma exacerbation (requiring emergency treatment or hospitalisation) within 4 weeks
of Visit 1; used oral corticosteroids within 4 weeks or depot steroids within 12 weeks of
Visit 1; a pre-bronchodilator FEV1 % predicted of less than 50%, smoking history of
10 pack-years or more
Interventions 1. Salmeterol/fluticasone 50/250 µg bdx 1DPI
2. Formoterol/budesonide 6/200 µg bdx 2DPI
26Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid
for chronic asthma: serious adverse events (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dahl 2006 (Continued)
Outcomes The primary efficacy measure was the number of exacerbations, expressed as a rate over
the 24-week treatment period
SAE data described in paper only as “No deaths in the study and only a small proportion
of patients reported serious AEs”
SAE data obtained from sponsors website
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patientswere assigned to study treatment in
accordance with the randomisation sched-
ule from the Interactive Voice Recognition
System, which was part of the GSK System
for the Central Allocation of Medication
Allocation concealment (selection bias) Low risk Blinded study medication was packed and
supplied by GlaxoSmithKline (GSK). All
treatment packs contained both Diskus/
Accuhaler and Turbuhaler devices (either
active Diskus/Accuhaler + placebo Tur-
buhaler, or active Turbuhaler + placebo
Diskus/Accuhaler) and looked identical
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, double-dummy
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1258/1397 (90%) completed the study
Selective reporting (reporting bias) Low risk SAE data found on website
Independent Outcome Assessment
Asthma-related serious adverse events
High risk No independent outcome assessment
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Methods Study design: a randomised, double-blind, double-dummy, multicentre, parallel-group
study over 24 weeks fromDecember 2003 toMarch 2005 at 235 centres in 16 countries.
Argentina (15), Australia (22), Bulgaria (9), Czech Republic (12), Great Britain (25),
Hungary (27), India (7),Malaysia (4),Mexico (15), theNetherlands (24), the Philippines
(8), Poland (29), South Korea (7), South Africa (26), Thailand (4), Vietnam (1). Run-
in 2 weeks
Participants Population: 3335 adolescents and adults (12 to 83) years with persistent asthma
Baseline characteristics: mean age 38 years. FEV1 73%predicted. Concomitant inhaled
corticosteroids used by 100% of participants. Run-in on previous dose of ICS alone
(LABA discontinued in the 47% of participants taking it previously)
Inclusion criteria: outpatients aged 12 years or over with a diagnosis of asthma for at
least 6 months and using ICS for at least 3 months. FEV1 %predicted of 50% or greater,
bronchodilator reversibility by an increase of at least 12% in FEV1 following terbutaline
1 mg and at least 1 asthma exacerbation in the previous 1 to 12 months, using reliever
medication on at least 5 of the last 7 days of the 2-week run-in
Combination therapy, if used, was discontinued and replaced with ICS alone, at least 4
weeks prior to study start (screening visit)
Exclusion criteria: patients using systemic corticosteroids or with respiratory infections
affecting asthma control within 30 days of study entry were excluded
Interventions 1. Salmeterol/fluticasone 25/125 µg bd x 2 pMDI
2. Formoterol/budesonide 12/400 µg bd x 1 DPI (reported as 9/320 delivered dose in
the paper)
3. Single inhaler therapy arm not included in this review
Outcomes The primary outcome variable was time to first severe asthma exacerbation, defined
as deterioration in asthma leading to at least one of the following: - hospitalisation or
emergency room treatment due to asthma, or oral corticosteroid treatment due to asthma
for at least 3 days, as judged by the investigator
SAE data reported in the paper and asthma-related SAE data obtained from AstraZeneca
(data on file). There was 1 death in the salmeterol/fluticasone group due to cardiac failure
and 1 death in the single inhaler therapy group due to respiratory failure (arm is not
included in this review)
Notes Sponsored by AstraZeneca
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation schedule was com-
puter-generated at AstraZeneca Research
and Development, Charnwood, UK.
Within each centre, patients were ran-
domised strictly sequentially as they be-
came eligible
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Kuna 2007 (Continued)
Allocation concealment (selection bias) Low risk Individual treatment codes and code en-
velopes (indicating the treatment alloca-
tion for each randomised patient) were
provided, but code envelopes were to be
opened only in case of medical emergen-
cies
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, double-dummy
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3172/3335 (95%) completed the study
Selective reporting (reporting bias) Low risk SAE data obtained from paper and spon-
sors
Independent Outcome Assessment
Asthma-related serious adverse events
High risk No independent outcome assessment
Maspero 2010
Methods Study design: this was a 52-week, randomised, multicentre, parallel-group, open-label,
evaluator-blinded study conducted at 27 clinical sites in South America
Participants Population: 404 adults (> 12 years of age) with persistent asthma
Baseline characteristics: mean age 36 years, FEV1 77% predicted, all had received ICS
(with or without LABA) for at least 12 weeks
Inclusion criteria: patients included in the study were 12 years or older, diagnosed
with persistent asthma of ≥12 months, had a forced expiratory volume in 1 second
(FEV1) ≥50% predicted values, received medium- or high-dose ICS with or without
LABA for ≥12 weeks before screening, and were on a stable regimen for >= 2 weeks
before screening. Additional inclusion criteria were evidence of β2-reversibility (increase
in FEV1 of ≥ 12% and ≥ 200 mL within 10 to 15 minutes of SABA use); normal
electrocardiogram (ECG), clinical laboratory tests, and chest radiograph; and adequate
contraceptive precautions for women of childbearing age
Exclusion criteria: patients were excluded if they demonstrated a change > 20% in
FEV1; required use of >12 inhalations of
SABA or two nebulised treatments with 2.5 mg salbutamol on 2 consecutive days at any
time between the screening and baseline visits; experienced a clinically judged deteriora-
tion (deterioration resulting in emergency treatment, hospitalisation, or treatment with
additional asthma medication other than SABA); had intraocular pressure ≥22 mmHg
in either eye, glaucoma or evidence of cataract(s) at screening; was a current smoker (had
smoked within the previous year) or ex-smoker (> 10 pack-years); received emergency
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Maspero 2010 (Continued)
treatment for airway obstruction in the past 3 months; or suffered a respiratory infection
within 2 weeks before screening
Interventions 1. Mometasone/formoterol 100/5 (n = 141) or 200/5 (n = 130) µg 2 puffs twice daily
2. Fluticasone/salmeterol 125/25 (n = 68) or 250/25 (n = 65) µg 2 puffs twice daily
Delivered byMDI and spacers were not permitted. Dose allocated according to previous
ICS use of the participant
Outcomes Primary outcome: adverse events
Notes Sponsored by Merck and Co. Two deaths occurred (electrocution and gastric cancer)
and these were both in mometasone/formoterol 200/10 group (see FDA report at www.
fda.gov/downloads/Drugs/.../UCM224593.pdf
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Evaluator blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Over 80% completed study in each arm
Selective reporting (reporting bias) Unclear risk Mortality details obtained from FDA re-
port
Independent Outcome Assessment
Asthma-related serious adverse events
High risk Not reported
Papi 2007
Methods Study design: a randomised, double-blind, multicentre, parallel-group study over 12
weeks from November 2004 to June 2005 at 12 outpatient respiratory clinics in Europe
(Poland (6) Ukraine (6)). Run-in 2 weeks
Participants Population: 228 adults (18 to 65) years with moderate to severe persistent asthma.
Baseline characteristics: mean age 48 years. FEV1 67% predicted. Concomitant in-
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Papi 2007 (Continued)
haled corticosteroids used by 100% of participants. Average ICS dose 731 µg/day (BDP
equivalent). Run in on ICS alone (no other anti-asthma medication permitted)
Inclusion criteria: clinical diagnosis of moderate to severe persistent asthma for at least
6 months, FEV1 % predicted between 50% to 80%, bronchodilator reversibility by an
increase of at least 12% in FEV1 (or, alternatively, of 200 ml) over baseline measured 30
min after 2 puffs (2 x 100 µg) of inhaled salbutamol administered via pMDI. Treatedwith
ICS at a daily dose of less than1000 µg of BDP-equivalent and had asthma symptoms
not adequately controlled as defined by: presence of daily symptoms at least once a week,
night-time symptoms at least twice a month and daily use of short-acting beta2-agonists.
Exclusion criteria: COPD, current or ex-smokers (more than 10 pack-years); severe
asthma exacerbation or symptomatic infection of the airways in the previous 8 weeks;
more than3 courses of oral corticosteroids or hospitalisationdue to asthma in the previous
6 months; treatment with LABAs, anticholinergics or antihistamines in the previous 2
weeks, and/or with topical or intranasal corticosteroids and leukotriene antagonists in
the previous 4 weeks, change of ICS dose in the previous 4 weeks
Interventions 1. Beclomethasone/formoterol 100/6 µg x 2 bd
2. Fluticasone/salmeterol 125/25 µg x 2 bd
Delivery was via pMDI
Outcomes The primary outcome variable was morning predose PEF measured by patients in the
last 2 weeks of treatment period (weeks 11 and 12). No serious adverse events reported in
either arm of the trial and the absence of deaths and hospitalisations has been confirmed
by Chiesi; no details of one of the patients withdrawn due to “Development of an
exclusion criteria”
Notes Sponsored by Chiesi
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was in balanced-block de-
sign stratified by centres
Allocation concealment (selection bias) Low risk “Each patient was identified with a ran-
domisation number, from 001 to 260 (in
blocks of four); each investigator assigned
the lowest available randomisation number
at each site.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind but not double-
dummy and inhalers were different shape
and size but this was “masked” using a non-
removable external covering for the inhalers
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as double-blind but not double-
dummy and inhalers were different shape
and size but this was “masked” using a non-
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removable external covering for the inhalers
Incomplete outcome data (attrition bias)
All outcomes
Low risk 225/228 (99%) completed the study
Selective reporting (reporting bias) Low risk “During the study no deaths or hospital-
izations occurred.” Data on file at Chiesi
Independent Outcome Assessment
Asthma-related serious adverse events
High risk No independent outcome assessment
Ringdal 2002
Methods Study design: a randomised, double-blind, double-dummy, multicentre, parallel-group
study over 12 weeks from May 1998 to June 1999 at 52 primary care practices and
hospital respiratory units in 11 countries (Austria (4), Belgium(4), Croatia (2), Denmark
(4), Finland (2), Germany (7), Italy (3), Norway (5), Russia (2), Slovakia (3), United
Kingdom (16)). Run-in 2 weeks
Participants Population: 428 adolescents and adults (16 to 75) years with moderate-to-severe asthma
who were uncontrolled on existing corticosteroid therapy
Baseline characteristics:mean age 47 years. FEV1 69% predicted.Concomitant inhaled
corticosteroids used by 100% of participants. Run-in on previous dose of ICS (no LABA
allowed in previous 2 weeks before recruitment).
Inclusion criteria: aged 16 to 75 years with a documented clinical history of asthma
currently receiving 1000 to 1600 µg/day of budesonide, beclomethasone dipropionate
or flunisolide, or 500 to 800 µg/day fluticasone propionate, for at least 4 weeks before
Visit 1
At the end of run-in, FEV1 % predicted of 50% to 85% at any of Visits 1 or 2/2A
(bronchodilators withheld for 6 hours), bronchodilator reversibility by an increase of
at least 15% in FEV1 over baseline 15 minutes after inhaling 400 µg of salbutamol at
Visit 1 or 2/2A, and a symptom score (day and night combined) of at least 2 or relief
bronchodilator use on at least 2 separate occasions (any dose) per day on at least 4 of the
last 7 days of the run-in period
Exclusion criteria: a smoking history of 10 pack-years or more, an asthma exacerbation
or upper or lower respiratory tract infection within the previous month, systemic or
nasal steroids or anti leukotrienes within the previous 4 weeks, or long-acting/oral/slow-
release beta2-agonists in the previous 2 weeks before Visit 1
Interventions 1. Salmeterol/fluticasone 50/250 µg bd via Diskus
2. Formoterol (12 µg bd) + budesonide (800 µg bd) via separate turbohalers
Outcomes The primary efficacy measure was mean PEFam over the week prior to the end of treat-
ment (Week 12)
SAE data obtained from sponsor’s website and also reported in the paper publication
Notes Sponsored by GSK
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Ringdal 2002 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomisation code was generated us-
ing the Glaxo Wellcome computer pro-
gram ’Patient Allocation for Clinical Trials’
(block size of 4) andnon-overlapping sets of
treatment numbers were allocated to each
centre. Treatment numbers were allocated
at Visit 2 in consecutive order, starting with
the lowest number available at that centre
Allocation concealment (selection bias) Low risk Numbered treatment packs of study drugs
were labelled to ensure that both patients
and investigators were blinded to the treat-
ment allocation, and the randomisation
codes were not revealed to investigators or
other study participants until after recruit-
ment, treatment, data collection and anal-
yses were complete
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, double-dummy
Incomplete outcome data (attrition bias)
All outcomes
Low risk 379/428 (89%) completed the study
Selective reporting (reporting bias) Low risk SAE reported in paper and on sponsor’s
trial report
Independent Outcome Assessment
Asthma-related serious adverse events
High risk No independent outcome assessment
SAM 40010
Methods Study design: a randomised, double-blind, double-dummy, multicentre, parallel-group
study over 12 weeks from January 2000 to July 2000 at 50 centres in Europe (Belgium,
Denmark, Germany, Ireland, Poland and The Netherlands). Run-in 2 to 4 weeks
Participants Population: 373 adolescents and adults with asthma that is poorly controlled by low
doses of inhaled corticosteroid
Baseline characteristics: mean age 42 years. Concomitant inhaled corticosteroids used
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SAM 40010 (Continued)
by 100% of participants. No details of treatment given during run-in
Inclusion criteria: aged 12 years and older with reversible airways obstruction who re-
mained symptomatic with inhaled corticosteroid treatment (400 to 500 µg/day budes-
onide or equivalent), for at least 4 weeks prior to Visit 1 (start of the run-in period),
had a clinical history of asthma with symptoms including cough, wheeze and shortness
of breath requiring treatment with short-acting beta2-agonist for a period of at least 6
months, a mean morning PEF during the last 7 consecutive days of the run-in period of
between 50% and 85% of their PEF measured 15 minutes after administration of 400
µg of salbutamol at Visit 1, and had recorded a cumulative total symptom score (daytime
plus night-time) of at least 8 for the last 7 consecutive days of the run-in period
Exclusion criteria: not reported
Interventions 1. Salmeterol/fluticasone 50/100 µg bd via Diskus
2. Budesonide 200 µg bd + formoterol 6 µg bd via DPI
Outcomes The primary study endpoint was morning peak expiratory flow, assessed as the mean of
the morning PEF values recorded during the 12-week treatment period. SAE data avail-
able fromweb report. One death in formoterol/budesonide group due to gastrointestinal
obstruction, cardiac failure and septic shock
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation code was computer-gener-
ated using Patient Allocation for Clinical
Trials developed by GlaxoSmithKline re-
search and development
Allocation concealment (selection bias) Low risk Treatment numbers were assigned sequen-
tially to all eligible subjects startingwith the
lowest number available to the investigator
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, double-dummy
Incomplete outcome data (attrition bias)
All outcomes
Low risk 362/373 (97%) completed the study
Selective reporting (reporting bias) Low risk SAE data presented in web report
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Independent Outcome Assessment
Asthma-related serious adverse events
High risk No independent outcome assessment
SAM 40048
Methods Study design: a randomised, double-blind, double-dummy, multicentre, parallel-group
study over 12 weeks from August 2001 to September 2002 at 27 centres in Germany.
Run-in 2 weeks
Participants Population: 248 adults with moderate bronchial asthma.
Baseline characteristics: mean age 48 years. FEV1 65% predicted (at Visit 2 (baseline)
). Concomitant inhaled corticosteroids used by 100% of participants. No details of
treatment given during run-in
Inclusion criteria: aged 18 years and older with moderate asthma. FEV1 % predicted
between 50% to 80%, bronchodilator reversibility by an increase of at least 15% in
FEV1, inhaled corticosteroid (ICS) treatment 1000 µg beclomethasone dipropionate
(BDP)/day or equivalent; and symptomatic asthma
Exclusion criteria: exacerbations or emergency visits during the 4-week pre-study period
and smoking (more than 20 cigarettes per day)
Interventions 1. Salmeterol/fluticasone 50/250 µg bd via Diskus
2. Formoterol/budesonide 6/200µg bd via DPI
Outcomes The primary variable was the change in forced expiratory volume in 1 second (FEV1)
(% predicted), after 12 weeks of treatment compared to baseline
SAE data in web report
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The allocation of patients to the two treat-
ment groupswas undertaken according to a
predetermined randomisation schedule (in
a ratio of 1 to 1).” GSK data on file
Allocation concealment (selection bias) Low risk “The allocation was undertaken as a block
randomisation,with identical allocation ra-
tios in each study centre. Every investiga-
tor had to allocate the patient to the lowest
available number at visit 2. Adherence to
this randomisation schedule was checked
during the process of data management.”
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SAM 40048 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, double-dummy
Incomplete outcome data (attrition bias)
All outcomes
Low risk 235/248 (95%) completed the study
Selective reporting (reporting bias) Low risk SAE data in web report
Independent Outcome Assessment
Asthma-related serious adverse events
High risk No independent outcome assessment
AMD: adjustable maintenance dosing
BDF: budesonide
DPI: dry powder inhaler
COPD: chronic obstructive pulmonary disease
FDA: Food and Drug Administration
FEV1: forced expiratory volume in one second
FPS: fluticasone propionate and salmeterol inhaler
GCS: glucocorticosteroid
GSK: GlaxoSmithKline
IVRS: Interactive voice recording system
LABA: long-acting beta2-agonist
PEF: peak expiratory flow
pMDI: pressurised metered-dose inhaler
SABA: short-acting beta2-agonist
SAE: serious adverse event
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bleecker 2008 Review of 2 other studies (Busse 2008; Kuna 2007)
Dhillon 2006 Review of studies on BDP/formoterol
Hampel 2008 Single-dose study
Jung 2008 Fluticasone/salmeterol versus current care
Lee 2003 4-week cross-over study
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Lyseng-Williamson 2003 Pharmacoeconomic review of studies on fluticasone/salmeterol inhaler
BDP: beclometasone
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D A T A A N D A N A L Y S E S
Comparison 1. Fixed-dose formoterol/ICS versus salmeterol/fluticasone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 10 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Formoterol/budesonide vs
salmeterol/fluticasone
7 5935 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.03 [0.06, 16.44]
1.2
Formoterol/beclomethasone vs
salmeterol/fluticasone
1 228 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Formoterol/mometasone
vs salmeterol/fluticasone
1 404 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.46 [0.23, 85.40]
1.4 Formoterol/fluticasone vs
salmeterol/fluticasone
1 202 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.39 [0.15, 372.38]
2 All-cause non-fatal serious
adverse events
10 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
2.1 Formoterol/budesonide vs
salmeterol/fluticasone
7 5935 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.14 [0.82, 1.59]
2.2
Formoterol/beclomethasone vs
salmeterol/fluticasone
1 228 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Formoterol/mometasone
vs salmeterol/fluticasone
1 404 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.07 [0.40, 2.84]
2.4 Formoterol/fluticasone vs
salmeterol/fluticasone
1 202 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.14 [0.00, 6.82]
3 Asthma related non-fatal serious
adverse events
8 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
3.1 Formoterol/budesonide vs
salmeterol/fluticasone
7 5935 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.69 [0.37, 1.26]
3.2
Formoterol/beclomethasone vs
salmeterol/fluticasone
1 228 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 All-cause mortality (risk
difference)
10 Risk Difference (M-H, Fixed, 95% CI) Subtotals only
4.1 Formoterol/budesonide vs
salmeterol/fluticasone
7 5935 Risk Difference (M-H, Fixed, 95% CI) 9.36 [-0.00, 0.00]
4.2
Formoterol/beclomethasone vs
salmeterol/fluticasone
1 228 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.02, 0.02]
4.3 Formoterol/mometasone
vs salmeterol/fluticasone
1 404 Risk Difference (M-H, Fixed, 95% CI) 0.01 [-0.01, 0.02]
4.4 Formoterol/fluticasone vs
salmeterol/fluticasone
1 202 Risk Difference (M-H, Fixed, 95% CI) 0.01 [-0.02, 0.04]
5 All-cause non-fatal serious
adverse events (risk difference)
10 Risk Difference (M-H, Fixed, 95% CI) Subtotals only
38Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid
for chronic asthma: serious adverse events (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5.1 Formoterol/budesonide vs
salmeterol/fluticasone
7 5935 Risk Difference (M-H, Fixed, 95% CI) 0.00 [-0.00, 0.01]
5.2
Formoterol/beclomethasone vs
salmeterol/fluticasone
1 228 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.02, 0.02]
5.3 Formoterol/mometasone
vs salmeterol/fluticasone
1 404 Risk Difference (M-H, Fixed, 95% CI) 0.00 [-0.04, 0.05]
5.4 Formoterol/fluticasone vs
salmeterol/fluticasone
1 202 Risk Difference (M-H, Fixed, 95% CI) -0.01 [-0.04, 0.02]
6 Asthma-related non-fatal serious
adverse events (risk difference)
8 Risk Difference (M-H, Fixed, 95% CI) Subtotals only
6.1 Formoterol/budesonide vs
salmeterol/fluticasone
7 5935 Risk Difference (M-H, Fixed, 95% CI) -0.00 [-0.01, 0.00]
6.2
Formoterol/beclomethasone vs
salmeterol/fluticasone
1 228 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.02, 0.02]
Analysis 1.1. Comparison 1 Fixed-dose formoterol/ICS versus salmeterol/fluticasone, Outcome 1 All-cause
mortality.
Review: Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma:
serious adverse events
Comparison: 1 Fixed-dose formoterol/ICS versus salmeterol/fluticasone
Outcome: 1 All-cause mortality
Study or subgroup Formoterol/ICS Salmeterol/Fluticasone
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol/budesonide vs salmeterol/fluticasone
Busse 2008 0/427 0/406 0.0 [ 0.0, 0.0 ]
Dahl 2006 0/700 0/697 0.0 [ 0.0, 0.0 ]
Ringdal 2002 0/216 0/212 0.0 [ 0.0, 0.0 ]
Aalbers 2004 0/215 0/224 0.0 [ 0.0, 0.0 ]
SAM 40048 0/126 0/121 0.0 [ 0.0, 0.0 ]
SAM 40010 1/183 0/190 7.68 [ 0.15, 387.17 ]
Kuna 2007 0/1099 1/1119 0.14 [ 0.00, 6.94 ]
Subtotal (95% CI) 2966 2969 1.03 [ 0.06, 16.44 ]
Total events: 1 (Formoterol/ICS), 1 (Salmeterol/Fluticasone)
Heterogeneity: Chi2 = 2.02, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 0.02 (P = 0.98)
0.001 0.01 0.1 1 10 100 1000
Favours Formoterol/ICS Favours Salmeterol/Flutic
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(. . . Continued)
Study or subgroup Formoterol/ICS Salmeterol/Fluticasone
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
2 Formoterol/beclomethasone vs salmeterol/fluticasone
Papi 2007 0/115 0/113 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 115 113 0.0 [ 0.0, 0.0 ]
Total events: 0 (Formoterol/ICS), 0 (Salmeterol/Fluticasone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
3 Formoterol/mometasone vs salmeterol/fluticasone
Maspero 2010 2/271 0/133 4.46 [ 0.23, 85.40 ]
Subtotal (95% CI) 271 133 4.46 [ 0.23, 85.40 ]
Total events: 2 (Formoterol/ICS), 0 (Salmeterol/Fluticasone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
4 Formoterol/fluticasone vs salmeterol/fluticasone
Bodzenta-Lukaszyk 2011 1/101 0/101 7.39 [ 0.15, 372.38 ]
Subtotal (95% CI) 101 101 7.39 [ 0.15, 372.38 ]
Total events: 1 (Formoterol/ICS), 0 (Salmeterol/Fluticasone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Chi2 = 0.83, df = 2 (P = 0.66), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.2. Comparison 1 Fixed-dose formoterol/ICS versus salmeterol/fluticasone, Outcome 2 All-cause
non-fatal serious adverse events.
Review: Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma:
serious adverse events
Comparison: 1 Fixed-dose formoterol/ICS versus salmeterol/fluticasone
Outcome: 2 All-cause non-fatal serious adverse events
Study or subgroup Formoterol/ICS Salmeterol/Fluticasone
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol/budesonide vs salmeterol/fluticasone
SAM 40048 1/126 1/121 0.96 [ 0.06, 15.45 ]
SAM 40010 2/183 0/190 7.72 [ 0.48, 123.94 ]
Ringdal 2002 3/216 2/212 1.47 [ 0.25, 8.55 ]
Aalbers 2004 11/215 5/224 2.27 [ 0.84, 6.15 ]
Busse 2008 10/427 9/406 1.06 [ 0.43, 2.63 ]
Dahl 2006 11/700 20/697 0.55 [ 0.27, 1.12 ]
Kuna 2007 39/1099 31/1119 1.29 [ 0.80, 2.08 ]
Subtotal (95% CI) 2966 2969 1.14 [ 0.82, 1.59 ]
Total events: 77 (Formoterol/ICS), 68 (Salmeterol/Fluticasone)
Heterogeneity: Chi2 = 8.06, df = 6 (P = 0.23); I2 =26%
Test for overall effect: Z = 0.79 (P = 0.43)
2 Formoterol/beclomethasone vs salmeterol/fluticasone
Papi 2007 0/115 0/113 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 115 113 0.0 [ 0.0, 0.0 ]
Total events: 0 (Formoterol/ICS), 0 (Salmeterol/Fluticasone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
3 Formoterol/mometasone vs salmeterol/fluticasone
Maspero 2010 13/271 6/133 1.07 [ 0.40, 2.84 ]
Subtotal (95% CI) 271 133 1.07 [ 0.40, 2.84 ]
Total events: 13 (Formoterol/ICS), 6 (Salmeterol/Fluticasone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
4 Formoterol/fluticasone vs salmeterol/fluticasone
Bodzenta-Lukaszyk 2011 0/101 1/101 0.14 [ 0.00, 6.82 ]
Subtotal (95% CI) 101 101 0.14 [ 0.00, 6.82 ]
Total events: 0 (Formoterol/ICS), 1 (Salmeterol/Fluticasone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Chi2 = 1.14, df = 2 (P = 0.57), I2 =0.0%
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Analysis 1.3. Comparison 1 Fixed-dose formoterol/ICS versus salmeterol/fluticasone, Outcome 3 Asthma
related non-fatal serious adverse events.
Review: Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma:
serious adverse events
Comparison: 1 Fixed-dose formoterol/ICS versus salmeterol/fluticasone
Outcome: 3 Asthma related non-fatal serious adverse events
Study or subgroup Formoterol/ICS Salmeterol/Fluticasone
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol/budesonide vs salmeterol/fluticasone
Aalbers 2004 1/215 0/224 7.70 [ 0.15, 388.62 ]
SAM 40010 1/183 0/190 7.68 [ 0.15, 387.17 ]
Busse 2008 0/427 3/406 0.13 [ 0.01, 1.23 ]
SAM 40048 0/126 0/121 0.0 [ 0.0, 0.0 ]
Kuna 2007 13/1099 15/1119 0.88 [ 0.42, 1.86 ]
Dahl 2006 1/700 6/697 0.24 [ 0.05, 1.05 ]
Ringdal 2002 1/216 1/212 0.98 [ 0.06, 15.74 ]
Subtotal (95% CI) 2966 2969 0.69 [ 0.37, 1.26 ]
Total events: 17 (Formoterol/ICS), 25 (Salmeterol/Fluticasone)
Heterogeneity: Chi2 = 7.49, df = 5 (P = 0.19); I2 =33%
Test for overall effect: Z = 1.21 (P = 0.23)
2 Formoterol/beclomethasone vs salmeterol/fluticasone
Papi 2007 0/115 0/113 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 115 113 0.0 [ 0.0, 0.0 ]
Total events: 0 (Formoterol/ICS), 0 (Salmeterol/Fluticasone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.4. Comparison 1 Fixed-dose formoterol/ICS versus salmeterol/fluticasone, Outcome 4 All-cause
mortality (risk difference).
Review: Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma:
serious adverse events
Comparison: 1 Fixed-dose formoterol/ICS versus salmeterol/fluticasone
Outcome: 4 All-cause mortality (risk difference)
Study or subgroup Formoterol/ICS Salmeterol/Fluticasone
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Formoterol/budesonide vs salmeterol/fluticasone
Aalbers 2004 0/215 0/224 7.4 % 0.0 [ -0.01, 0.01 ]
Busse 2008 0/427 0/406 14.0 % 0.0 [ 0.00, 0.00 ]
Dahl 2006 0/700 0/697 23.5 % 0.0 [ 0.00, 0.00 ]
Kuna 2007 0/1099 1/1119 37.4 % 0.00 [ 0.00, 0.00 ]
Ringdal 2002 0/216 0/212 7.2 % 0.0 [ -0.01, 0.01 ]
SAM 40010 1/183 0/190 6.3 % 0.01 [ -0.01, 0.02 ]
SAM 40048 0/126 0/121 4.2 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 2966 2969 100.0 % 0.00 [ 0.00, 0.00 ]
Total events: 1 (Formoterol/ICS), 1 (Salmeterol/Fluticasone)
Heterogeneity: Chi2 = 1.02, df = 6 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
2 Formoterol/beclomethasone vs salmeterol/fluticasone
Papi 2007 0/115 0/113 100.0 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 115 113 100.0 % 0.0 [ -0.02, 0.02 ]
Total events: 0 (Formoterol/ICS), 0 (Salmeterol/Fluticasone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Formoterol/mometasone vs salmeterol/fluticasone
Maspero 2010 2/271 0/133 100.0 % 0.01 [ -0.01, 0.02 ]
Subtotal (95% CI) 271 133 100.0 % 0.01 [ -0.01, 0.02 ]
Total events: 2 (Formoterol/ICS), 0 (Salmeterol/Fluticasone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
4 Formoterol/fluticasone vs salmeterol/fluticasone
Bodzenta-Lukaszyk 2011 1/101 0/101 100.0 % 0.01 [ -0.02, 0.04 ]
Subtotal (95% CI) 101 101 100.0 % 0.01 [ -0.02, 0.04 ]
Total events: 1 (Formoterol/ICS), 0 (Salmeterol/Fluticasone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi2 = 1.37, df = 3 (P = 0.71), I2 =0.0%
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Analysis 1.5. Comparison 1 Fixed-dose formoterol/ICS versus salmeterol/fluticasone, Outcome 5 All-cause
non-fatal serious adverse events (risk difference).
Review: Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma:
serious adverse events
Comparison: 1 Fixed-dose formoterol/ICS versus salmeterol/fluticasone
Outcome: 5 All-cause non-fatal serious adverse events (risk difference)
Study or subgroup Formoterol/ICS Salmeterol/Fluticasone
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Formoterol/budesonide vs salmeterol/fluticasone
Aalbers 2004 11/215 5/224 7.4 % 0.03 [ -0.01, 0.06 ]
Busse 2008 10/427 9/406 14.0 % 0.00 [ -0.02, 0.02 ]
Dahl 2006 11/700 20/697 23.5 % -0.01 [ -0.03, 0.00 ]
Kuna 2007 39/1099 31/1119 37.4 % 0.01 [ -0.01, 0.02 ]
Ringdal 2002 3/216 2/212 7.2 % 0.00 [ -0.02, 0.02 ]
SAM 40010 2/183 0/190 6.3 % 0.01 [ -0.01, 0.03 ]
SAM 40048 1/126 1/121 4.2 % 0.00 [ -0.02, 0.02 ]
Subtotal (95% CI) 2966 2969 100.0 % 0.00 [ 0.00, 0.01 ]
Total events: 77 (Formoterol/ICS), 68 (Salmeterol/Fluticasone)
Heterogeneity: Chi2 = 7.46, df = 6 (P = 0.28); I2 =20%
Test for overall effect: Z = 0.79 (P = 0.43)
2 Formoterol/beclomethasone vs salmeterol/fluticasone
Papi 2007 0/115 0/113 100.0 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 115 113 100.0 % 0.0 [ -0.02, 0.02 ]
Total events: 0 (Formoterol/ICS), 0 (Salmeterol/Fluticasone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Formoterol/mometasone vs salmeterol/fluticasone
Maspero 2010 13/271 6/133 100.0 % 0.00 [ -0.04, 0.05 ]
Subtotal (95% CI) 271 133 100.0 % 0.00 [ -0.04, 0.05 ]
Total events: 13 (Formoterol/ICS), 6 (Salmeterol/Fluticasone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
4 Formoterol/fluticasone vs salmeterol/fluticasone
Bodzenta-Lukaszyk 2011 0/101 1/101 100.0 % -0.01 [ -0.04, 0.02 ]
Subtotal (95% CI) 101 101 100.0 % -0.01 [ -0.04, 0.02 ]
Total events: 0 (Formoterol/ICS), 1 (Salmeterol/Fluticasone)
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(. . . Continued)
Study or subgroup Formoterol/ICS Salmeterol/Fluticasone
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi2 = 0.88, df = 3 (P = 0.83), I2 =0.0%
-0.02 -0.01 0 0.01 0.02
Favours Formoterol/ICS Favours Salmeterol/Flutic
Analysis 1.6. Comparison 1 Fixed-dose formoterol/ICS versus salmeterol/fluticasone, Outcome 6 Asthma-
related non-fatal serious adverse events (risk difference).
Review: Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma:
serious adverse events
Comparison: 1 Fixed-dose formoterol/ICS versus salmeterol/fluticasone
Outcome: 6 Asthma-related non-fatal serious adverse events (risk difference)
Study or subgroup Formoterol/ICS Salmeterol/Fluticasone
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Formoterol/budesonide vs salmeterol/fluticasone
Aalbers 2004 1/215 0/224 7.4 % 0.00 [ -0.01, 0.02 ]
Busse 2008 0/427 3/406 14.0 % -0.01 [ -0.02, 0.00 ]
Dahl 2006 1/700 6/697 23.5 % -0.01 [ -0.01, 0.00 ]
Kuna 2007 13/1099 15/1119 37.4 % 0.00 [ -0.01, 0.01 ]
Ringdal 2002 1/216 1/212 7.2 % 0.00 [ -0.01, 0.01 ]
SAM 40010 1/183 0/190 6.3 % 0.01 [ -0.01, 0.02 ]
SAM 40048 0/126 0/121 4.2 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 2966 2969 100.0 % 0.00 [ -0.01, 0.00 ]
Total events: 17 (Formoterol/ICS), 25 (Salmeterol/Fluticasone)
Heterogeneity: Chi2 = 5.12, df = 6 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
2 Formoterol/beclomethasone vs salmeterol/fluticasone
Papi 2007 0/115 0/113 100.0 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 115 113 100.0 % 0.0 [ -0.02, 0.02 ]
-0.05 -0.03 0 0.03 0.05
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Study or subgroup Formoterol/ICS Salmeterol/Fluticasone
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 0 (Formoterol/ICS), 0 (Salmeterol/Fluticasone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.77), I2 =0.0%
-0.05 -0.03 0 0.03 0.05
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A D D I T I O N A L T A B L E S
Table 1. Details of the dose and type of medication used
Study ID Formoterol de-
vice
Formoterol
dose
ICS type and
dose
Salmeterol de-
vice
Salmeterol dose ICS type and
dose
Aalbers 2004 DPI 12 µg bd Budesonide 400
µg bd
DPI 50 µg bd Fluticasone 250
µg bd
Bodzenta-
Lukaszyk 2011
HFA pMDI
with AeroCham-
ber
10 µg bd Fluticasone 100
µg or 250 µg bd
HFA pMDI
with AeroCham-
ber
50 µg bd Fluticasone 100
µg or 250 µg bd
Busse 2008 pMDI 12 µg bd Budesonide 400
µg bd
DPI 50 µg bd Fluticasone 250
µg bd
Dahl 2006 DPI 12 µg bd Budesonide 400
µg bd
DPI 50 µg bd Fluticasone 250
µg bd
Kuna 2007 DPI 12 µg bd Budesonide 400
µg bd
pMDI 50 µg bd Fluticasone 250
µg bd
Maspero 2010 pMDI 10 µg bd Mometasone
200 µg or 400 µg
bd
pMDI 50 µg bd Fluticasone 250
µg or 500 µg bd
Papi 2007 pMDI 12 µg bd Beclometha-
sone extra fine
200 µg bd
pMDI 50 µg bd Fluticasone 250
µg bd
Ringdal 2002 DPI two separate
inhalers
12 µg bd Budesonide 800
µg bd
DPI 50 µg bd Fluticasone 250
µg bd
SAM 40010 DPI 6 µg bd Budesonide 200
µg bd
DPI 50 µg bd Fluticasone 100
µg bd
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Table 1. Details of the dose and type of medication used (Continued)
SAM 40048 DPI 6 µg bd Budesonide 200
µg bd
DPI 50 µg bd Fluticasone 250
µg bd
Doses shown are ex-actuator rather than delivered doses.
bd: twice a day
DPI: dry powder inhaler
ICS: inhaled corticosteroid
HFA: hydrofluoroalkane
pMDI: pressurised metered dose inhaler
Table 2. Details of the study participants, location and sponsors
Study ID Number
randomised
Duration Age Location Sponsors
Aalbers 2004 658 26 weeks (open ex-
tension)
12+ Europe AstraZeneca
Bodzenta-Lukaszyk
2011
202 12 weeks 18+ Europe Mundipharma
Busse 2008 1225 30 weeks 12+ USA AstraZeneca
Dahl 2006 1397 24 weeks 18+ Europe GlaxoSmithKline
Kuna 2007 3335 24 weeks 12+ Multinational AstraZeneca
Maspero 2010 404 52 weeks 12+ South America Merck
Papi 2007 228 12 weeks 18+ Europe Chiesi
Ringdal 2002 428 12 weeks 16+ Europe GlaxoSmithKline
SAM 40010 373 12 weeks 12+ Europe GlaxoSmithKline
SAM 40048 248 12 weeks 18+ Germany GlaxoSmithKline
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
CENTRAL (T he Cochrane Library) Quarterly
PSYCINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
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MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
WH A T ’ S N E W
Last assessed as up-to-date: 17 August 2011.
Date Event Description
17 August 2011 New search has been performed New search in August 2011 identified one new included study on 202
adults comparing formoterol and fluticasone with salmeterol and fluticasone
(Bodzenta-Lukaszyk 2011), and one new study on 404 adults comparing for-
moterol and mometasone with salmeterol and fluticasone (Maspero 2010).
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H I S T O R Y
Protocol first published: Issue 2, 2009
Review first published: Issue 1, 2010
Date Event Description
15 August 2011 Amended Typological error in abstract corrected (dose of formoterol changed from 50 µg to 12 µg)
C O N T R I B U T I O N S O F A U T H O R S
CJC: conception of the idea and co-writing of protocol, data extraction, analysis and writing the review and update.
TL: data extraction and co-writing of the review and update.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• NHS R&D, UK.
National Institute of Health Research: Programme Grant
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
No subgroup analysis was possible on the basis of age or dose-equivalence of inhaled corticosteroids.
I N D E X T E R M S
50Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid
for chronic asthma: serious adverse events (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Medical Subject Headings (MeSH)
Administration, Inhalation; Albuterol [administration & dosage; adverse effects; ∗analogs & derivatives]; Androstadienes [administra-
tion & dosage; adverse effects]; Anti-Asthmatic Agents [administration & dosage; ∗adverse effects]; Asthma [∗drug therapy; mortality];
Budesonide [administration & dosage; adverse effects]; Drug Therapy, Combination [adverse effects]; Ethanolamines [administration
& dosage; ∗adverse effects]; Glucocorticoids [administration & dosage; ∗adverse effects]; Randomized Controlled Trials as Topic
MeSH check words
Adolescent; Adult; Humans
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